CLARA, the renowned cancer research organization in Auvergne Rhone-Alpes, has announced its ambitious funding plans for 17 cancer research projects in 2024. The organization, backed by a host of contributors including the French National Cancer Institute (INCA), regional authorities, city councils, and cancer associations, has earmarked a hefty budget of 1.45 million euros for these initiatives.
Strategic Prioritization of Cancer Research
The selected projects for funding encompass a wide array of research areas. Notably, significant emphasis has been placed on ovarian cancer research and studies concerning perfluorinated compounds. These areas represent some of the most pressing challenges in current cancer research, and CLARA's investment will undoubtedly catalyze innovative solutions and breakthroughs.
Revolutionizing Patient Care and Treatment
The 'Preuve du concept' program, a collaborative effort with Lyonbiopole, is sponsoring three projects aimed at revolutionizing patient care. One standout initiative is the development of a novel digital tool designed to facilitate more effective shared decision-making between doctors and patients, thereby enhancing patient participation in cancer screenings.
Large-Scale Structuring Projects
Two key 'structuring projects' have also been identified. Asteropa, a participatory research project on perfluorinated compounds, is being led by the Centre Leon-Berard, while Oncostarter is backing 12 significant projects, including a cohort study focusing on ovarian cancer patients over the age of 70 and a study aimed at predicting chemotherapy responses in neuroendocrine tumors.
Over the past two decades, CLARA has demonstrated its unwavering commitment to cancer research, supporting more than 270 research projects with a total funding of 15 million euros. As we look towards 2024, CLARA continues its vital mission, driving forward the frontiers of cancer research and paving the way for a future free from cancer.